A critical review on purine and pyrimidine heterocyclic derivatives and their designed molecules in Cancer

This review investigates into the topic of purine and pyrimidine derivatives and their potential as anticancer agents. It thoroughly investigates their efficacy against various types of cancer cells and sheds light on the underlying mechanisms at play. The development of these derivatives has sparked immense interest, as they hold great promise for clinical use. They display a remarkable ability to hinder DNA synthesis and repair, as well as regulate the cell cycle, making them powerful weapons against cancer. Through this research, we explore the potential impact of these compounds on cancer treatment, including their ability to overcome challenges such as drug resistance and other complexities associated with the disease. This review critically evaluates and highlights the top-performing compounds for treating cancer, taking into consideration their efficacy, selectivity, and safety profiles. With its valuable insights, it serves as a valuable resource for further refining cancer treatment strategies. Additionally, the paper delves into the growing trend of cancer stem cell theory and its influence on the progress of personalized medicine in the realm of cancer therapy. This underscores the tremendous potential of molecular data in guiding the development of more effective treatments, further emphasizing the crucial role of personalized epigenomic therapy. By stressing the importance of innovative approaches to overcome challenges and optimize treatment outcomes, the review illuminates the significance of ongoing research in this field. This complete study explores into the powerful potential of purine and pyrimidine derivatives as a means of combating cancer, providing groundbreaking insights and potential breakthroughs for this critical area of medical research. For medical professionals and researchers engaged in the fight against cancer, this review is an invaluable resource that sheds light on the promising anticancer effects of these derivatives. Additionally, it paves the way for exciting advancements in both laboratory and clinical applications in the field of cancer treatment. By the review designed purine derivatives at C2 with C6 and C9 are active against Brest cancer cell lines, C2, C4 and C7 against colon and blood cancer, C4 against kidney cancer cells, C6 against liver, lung, luekamia and colon cancer cell line, C7, Brest, liver and metastatic colon cancer and C8 substituted are active against majority of cancer cell lines. With respect to pyrimidine derivatives tetra substituents at 1, 2, 4 and 6 are active against Metastatic cancer in Brest, pancreas and liver cells, 2, 4 and 6 tri substituted against Metastatic cancer in Brest, pancreas and liver, against Arora kinase, leukemia and colon cancer, Further they are active against non small cell lung cancer and CNS cell lines respectively.